Vanda Pharmaceuticals (VNDA)

Executive Summary

Vanda Pharmaceuticals (NASDAQ: VNDA) is a Washington DC-based biopharmaceutical company focused on developing and commercializing innovative small molecule therapies for neuropsychiatric and sleep-wake disorders. Leveraging genetics, genomics, and pharmacogenetics, Vanda aims to identify patient populations most likely to benefit from its therapeutics. The company has two FDA-approved products: Fanapt (iloperidone) for schizophrenia and Hetlioz (tasimelteon) for non-24-hour sleep-wake disorder. Vanda also markets Hetlioz for Smith-Magenis syndrome and is developing a pipeline of assets targeting high unmet medical needs, including tradipitant for gastroparesis and motion sickness, VQW-765 for performance anxiety, and VCA-894A for Charcot-Marie-Tooth disease (CMT). Despite a mixed clinical track record, Vanda maintains a steady revenue base from its commercial products and a disciplined R&D approach.

Upcoming Catalysts (preview)

• Q3 2026VCA-894A Phase 1/2 top-line data in Charcot-Marie-Tooth disease30% success
• Q2 2026Tradipitant Phase 3 gastroparesis data readout or NDA submission40% success
• Q4 2026VQW-765 Phase 2 results and Phase 3 initiation in performance anxiety35% success